C2 PHARMA,  a company involved in manufacturing and supplying ophthalmic and niche active pharmaceutical ingredients (APIs), reported the approval of a C-DMF for Pilocarpine Nitrate, an API manufactured by its Brazilian partner Anidro do Brasil.

Pilocarpine Nitrate is an ophthalmic API extracted from the Jaborandi plant and is primarily used for treating glaucoma and other specific diagnostic applications. C2 PHARMA the main supporter of the “Partnership for a Better World” initiative meant to drive sustainable principles and eco-friendly harvesting practices of the Jaborandi plant in the wild.

“After a rigorous four-year journey, we are proud to have met numerous requests from the Chinese Health Authorities (CDE) and are finally able to provide this API to the Chinese market,” said regulatory affairs manager, Anastasia Motorina. “Collaboration was truly key here with our manufacturing partner Anidro do Brasil to implement the CDE requirements along with the help of our partner Guangzhou Greensyn.”